A detailed history of Susquehanna International Group, LLP transactions in Immunome Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 51,631 shares of IMNM stock, worth $574,136. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,631
Previous 29,711 73.78%
Holding current value
$574,136
Previous $359,000 110.03%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$11.7 - $16.51 $256,463 - $361,899
21,920 Added 73.78%
51,631 $754,000
Q2 2024

Aug 15, 2024

SELL
$11.54 - $22.11 $3.34 Million - $6.41 Million
-289,803 Reduced 90.7%
29,711 $359,000
Q1 2024

May 07, 2024

BUY
$11.01 - $27.34 $3.13 Million - $7.78 Million
284,687 Added 817.43%
319,514 $7.89 Million
Q4 2023

Feb 14, 2024

BUY
$7.3 - $10.73 $70,795 - $104,059
9,698 Added 38.59%
34,827 $372,000
Q3 2023

Nov 14, 2023

BUY
$6.17 - $9.16 $47,293 - $70,211
7,665 Added 43.89%
25,129 $209,000
Q2 2023

Aug 11, 2023

BUY
$4.7 - $7.91 $23,091 - $38,861
4,913 Added 39.14%
17,464 $138,000
Q1 2023

May 16, 2023

SELL
$3.26 - $5.69 $31,012 - $54,128
-9,513 Reduced 43.12%
12,551 $62,000
Q4 2022

Feb 14, 2023

BUY
$2.21 - $5.0 $48,761 - $110,320
22,064 New
22,064 $48,000
Q2 2022

Aug 15, 2022

SELL
$2.24 - $5.79 $48,641 - $125,729
-21,715 Reduced 64.31%
12,052 $39,000
Q1 2022

May 16, 2022

SELL
$3.88 - $13.99 $122,926 - $443,231
-31,682 Reduced 48.41%
33,767 $192,000
Q4 2021

Feb 14, 2022

BUY
$12.96 - $23.44 $85,121 - $153,953
6,568 Added 11.15%
65,449 $848,000
Q3 2021

Nov 15, 2021

BUY
$12.5 - $27.76 $736,012 - $1.63 Million
58,881 New
58,881 $1.43 Million

Others Institutions Holding IMNM

About Immunome Inc.


  • Ticker IMNM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,127,400
  • Market Cap $135M
  • Description
  • Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...
More about IMNM
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.